Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antisense Oligonucleotide Therapy in Spinal Muscular Atrophy: An Observational Study in China

NCT05187260 is registered in ClinicalTrials.gov with First Affiliated Hospital of Fujian Medical University as lead sponsor.

NCT NCT05187260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05187260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antisense Oligonucleotide Therapy in Spinal Muscular Atrophy: An Observational Study in China
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
January 31, 2024
Enrollment
1,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy